SARS-CoV-2 Protein Deposition Enhances Renal Complement Activation and Aggravates Kidney Injury in Membranous Nephropathy After COVID-19

IF 5.7 2区 医学 Q1 UROLOGY & NEPHROLOGY Kidney International Reports Pub Date : 2024-11-01 DOI:10.1016/j.ekir.2024.08.006
Guoqin Wang , Lei Yang , Xiaoyi Xu , Weiyi Guo , Lijun Sun , Yanyan Wang , Wenrong Cheng , Nan Ye , Lingqiang Kong , Xiaoyi Zhao , Hong Cheng
{"title":"SARS-CoV-2 Protein Deposition Enhances Renal Complement Activation and Aggravates Kidney Injury in Membranous Nephropathy After COVID-19","authors":"Guoqin Wang ,&nbsp;Lei Yang ,&nbsp;Xiaoyi Xu ,&nbsp;Weiyi Guo ,&nbsp;Lijun Sun ,&nbsp;Yanyan Wang ,&nbsp;Wenrong Cheng ,&nbsp;Nan Ye ,&nbsp;Lingqiang Kong ,&nbsp;Xiaoyi Zhao ,&nbsp;Hong Cheng","doi":"10.1016/j.ekir.2024.08.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>COVID-19 has been reported to be associated with the occurrence and recurrence of membranous nephropathy (MN). The clinicopathological characteristics and complement system activation of MN after COVID-19 are unclear.</div></div><div><h3>Methods</h3><div>A total of 38 patients with biopsy-proven MN who developed new-onset proteinuria after COVID-19 were enrolled in this study. One hundred patients with primary MN diagnosed before the COVID-19 pandemic were the control. Renal immunohistochemical staining for SARS-CoV-2 nucleocapsid protein was performed in 38 patients with MN after COVID-19. Serum membrane attack complex (MAC) was detected by enzyme-linked immunosorbent assay. Glomerular staining for the complement proteins in different pathways were detected by immunohistochemistry.</div></div><div><h3>Results</h3><div>Thirteen of 38 patients had positive staining for SARS-CoV-2 nucleocapsid protein. Compared with the control patients, the clinical manifestations were more severe in patients after COVID-19. Patients with positive SARS-CoV-2 staining had a higher proportion of nephrotic syndrome, lower level of serum albumin, and greater severity of renal interstitial fibrosis than those of patients with negative SARS-CoV-2 staining. Serum MAC level and renal MAC staining intensity of MN after COVID-19 were significantly higher than those of the control patients. MAC expression in MN patients with positive SARS-CoV-2 staining was stronger than that in both control patients and MN after COVID-19 with negative SARS-CoV-2 staining. The expression trend of factor H was consistent with that of MAC.</div></div><div><h3>Conclusion</h3><div>Excessive activation of the complement system aggravated symptoms in MN after COVID-19. Therapeutic strategy targeting the complement system may need to be considered.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney International Reports","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468024924018783","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

COVID-19 has been reported to be associated with the occurrence and recurrence of membranous nephropathy (MN). The clinicopathological characteristics and complement system activation of MN after COVID-19 are unclear.

Methods

A total of 38 patients with biopsy-proven MN who developed new-onset proteinuria after COVID-19 were enrolled in this study. One hundred patients with primary MN diagnosed before the COVID-19 pandemic were the control. Renal immunohistochemical staining for SARS-CoV-2 nucleocapsid protein was performed in 38 patients with MN after COVID-19. Serum membrane attack complex (MAC) was detected by enzyme-linked immunosorbent assay. Glomerular staining for the complement proteins in different pathways were detected by immunohistochemistry.

Results

Thirteen of 38 patients had positive staining for SARS-CoV-2 nucleocapsid protein. Compared with the control patients, the clinical manifestations were more severe in patients after COVID-19. Patients with positive SARS-CoV-2 staining had a higher proportion of nephrotic syndrome, lower level of serum albumin, and greater severity of renal interstitial fibrosis than those of patients with negative SARS-CoV-2 staining. Serum MAC level and renal MAC staining intensity of MN after COVID-19 were significantly higher than those of the control patients. MAC expression in MN patients with positive SARS-CoV-2 staining was stronger than that in both control patients and MN after COVID-19 with negative SARS-CoV-2 staining. The expression trend of factor H was consistent with that of MAC.

Conclusion

Excessive activation of the complement system aggravated symptoms in MN after COVID-19. Therapeutic strategy targeting the complement system may need to be considered.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
SARS-CoV-2 蛋白沉积会增强肾脏补体激活,加重 COVID-19 后膜性肾病的肾损伤
据报道,COVID-19 与膜性肾病(MN)的发生和复发有关。COVID-19 后 MN 的临床病理特征和补体系统激活情况尚不清楚。本研究共纳入了 38 例经活检证实的 MN 患者,这些患者在 COVID-19 后出现了新发蛋白尿。100 名在 COVID-19 大流行之前确诊的原发性 MN 患者为对照组。对 38 例 COVID-19 后的 MN 患者的肾脏进行了 SARS-CoV-2 核壳蛋白免疫组化染色。通过酶联免疫吸附试验检测血清膜攻击复合物(MAC)。免疫组化法检测了肾小球不同途径的补体蛋白染色。38 名患者中有 13 人的 SARS-CoV-2 核壳蛋白染色呈阳性。与对照组患者相比,COVID-19 患者的临床表现更为严重。与 SARS-CoV-2 染色阴性的患者相比,SARS-CoV-2 染色阳性的患者肾病综合征比例更高,血清白蛋白水平更低,肾间质纤维化程度更严重。COVID-19 后 MN 的血清 MAC 水平和肾脏 MAC 染色强度明显高于对照组患者。SARS-CoV-2染色阳性的MN患者的MAC表达强于SARS-CoV-2染色阴性的对照组患者和COVID-19后的MN患者。因子 H 的表达趋势与 MAC 的表达趋势一致。补体系统的过度激活加重了 COVID-19 后 MN 的症状。可能需要考虑针对补体系统的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Kidney International Reports
Kidney International Reports Medicine-Nephrology
CiteScore
7.70
自引率
3.30%
发文量
1578
审稿时长
8 weeks
期刊介绍: Kidney International Reports, an official journal of the International Society of Nephrology, is a peer-reviewed, open access journal devoted to the publication of leading research and developments related to kidney disease. With the primary aim of contributing to improved care of patients with kidney disease, the journal will publish original clinical and select translational articles and educational content related to the pathogenesis, evaluation and management of acute and chronic kidney disease, end stage renal disease (including transplantation), acid-base, fluid and electrolyte disturbances and hypertension. Of particular interest are submissions related to clinical trials, epidemiology, systematic reviews (including meta-analyses) and outcomes research. The journal will also provide a platform for wider dissemination of national and regional guidelines as well as consensus meeting reports.
期刊最新文献
Disparities in Kidney Care: Empowering Patients With Data Efficacy and Safety of Subcutaneous Rituximab in Idiopathic Nephrotic Syndrome Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation Exuberant Endothelial C5b-9 Formation in Recurrent and De Novo Posttransplant Thrombotic Microangiopathy TRPC6-Calpain-1 Axis Promotes Tubulointerstitial Inflammation by Inhibiting Mitophagy in Diabetic Kidney Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1